問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3348Cases

2019-01-01 - 2026-06-30

Phase III

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)

  • Condition/Disease

    Hormone Receptor-positive, HER2-negative Early Breast Cancer

  • Test Drug

    KISQALI

Participate Sites
9Sites

Recruiting9Sites

2023-10-01 - 2026-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2024-12-02 - 2027-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2015-12-01 - 2021-05-20

Phase I/II

A Phase 1b/2 Study of PEP503 (Radioenhancer) with Radiotherapy in Combination with Concurrent Chemotherapy for Patients with Head and Neck Cancer

  • Condition/Disease

    Head and Neck Cancer

  • Test Drug

    PEP503

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

趙坤山
China Medical University Hospital

Division of Hematology & Oncology

2006-11-01 - 2008-11-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2015-06-01 - 2018-09-30

Phase II

A Phase 2, randomized, multiple-dose, double-blind, placebo-controlled study of JKB-122 in treating subjects with non-alcoholic fatty liver disease (NAFLD)

  • Condition/Disease

    non-alcoholic fatty liver disease (NAFLD)

  • Test Drug

    JKB-122

Participate Sites
7Sites

Terminated7Sites

陳明堯
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

黃怡翔
Taipei Veterans General Hospital

2017-01-11 - 2019-01-22

Phase III

A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Compared with Latanoprost Ophthalmic Solution 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension- PEONY Study

  • Condition/Disease

    Open Angle Glaucoma or Ocular Hypertension

  • Test Drug

    DE-117

Participate Sites
9Sites

Terminated9Sites

2016-11-01 - 2022-10-28

Phase III

A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer

  • Condition/Disease

    metastatic hormone-sensitive prostate cancer

  • Test Drug

    BAY 1841788/ODM-201(Darlutamide)

Participate Sites
8Sites

Recruiting6Sites

黃逸修
Taipei Veterans General Hospital

馮思中
Linkou Chang Gung Medical Foundation

2017-02-01 - 2019-05-09

Phase III

Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement. (EdoxabaN Treatment versus VKA in patients with AF undergoing PCI ( ENTRUST-AF PCI)

  • Condition/Disease

    Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement

  • Test Drug

    Edoxaban (DU-176b)

Participate Sites
13Sites

Terminated11Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2017-01-05 - 2019-12-31

Others

An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

  • Condition/Disease

    Solid Tumors

  • Test Drug

    TECENTRIQ

Participate Sites
6Sites

Recruiting4Sites

Terminated1Sites

趙毅
Taipei Veterans General Hospital

陳仁熙
Linkou Chang Gung Medical Foundation

1 206 207 208 209 210 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB